Korzyści ze stosowania lisinoprilu w chorobach układu sercowo-naczyniowego i chorobach nerek. Czego spodziewać się po badaniu HALT-PKD? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2012
Słowa kluczowe:
lisinopril, choroby układu sercowo-naczyniowego, choroby nerek, ADPKD
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zastosowanie w praktyce inhibitorów konwertazy angiotensyny (ACE-I, angiotensin converting-enzyme inhibitors) uważa się za jedno z ważniejszych osiągnięć farmakoterapii. Lisinopril ma zastosowanie w leczeniu nadciśnienia tętniczego samoistnego i naczyniowo-nerkowego, zarówno w monoterapii, jak i w leczeniu skojarzonym z innymi lekami hipotensyjnymi, w niewydolności serca w skojarzeniu z lekami moczopędnymi oraz w określonych przypadkach z preparatami naparstnicy, po zawale mięśnia sercowego oraz w cukrzycowej chorobie nerek. Wyniki badania HALT-PKD pomogą odpowiedzieć na pytanie, czy doskonała kontrola ciśnienia tętniczego może mieć znaczenie w zapobieganiu progresji przewlekłej choroby nerek we wszystkich stadiach, czy może tylko w bardziej/mniej zaawansowanych, i czy jest to związane ze zmniejszeniem liczby powikłań sercowo-naczyniowych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Tomaszuk-Kazberuk, A., & Małyszko, J. (2012). Korzyści ze stosowania lisinoprilu w chorobach układu sercowo-naczyniowego i chorobach nerek. Czego spodziewać się po badaniu HALT-PKD?. Medycyna Faktów , 5(4(17), 14-20. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2436
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Patchett A.A., Harris E., Tristram E.W. et al.: A new class of angiotensin-converting enzyme inhibitors. Nature 1980; 288: 280-283.
2. Opie L.H.: Inhibitory konwertazy angiotensyny. Postęp trwa. Via Medica, Gdańsk 2000: 219-223.
3. Barylski M., Górska-Ciebiada M.: Lizinopril – praktyczne wskazania do stosowania w terapii chorób układu sercowo-naczyniowego. Geriatria 2011; 5: 110-121.
4. Gu Q., Burt V.L., Dillon C.F. et al.: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. Circulation 2012; 126(17): 2105-2114.
5. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
6. Izzo J.L., Weinberg M.S., Hainer J.W. et al.: Antihypertensive Efficacy of Candersartan-Lisinopril in Combination vs Up-Titration of Lisinopril: The AMAZE Trials. J. Clin. Hypertens. 2004; 6: 485-93.
7. Malacco E., Santonastaso M., Vari N.A. et al.: Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-65.
8. Belz G.G., Kirch W., Kleinbloesem C.H.: Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin. Pharmacokinet. 1988 Nov; 15(5): 295-318.
9. Shionoiri H., Ueda S., Gotoh E. et al.: Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. J. Cardiovasc. Pharmacol. 1990; 16(6): 905-9.
10. Thürig C., Böhlen L., Schneider M.: Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur. J. Clin. Pharmacol. 1995; 49(1-2): 21-6.
11. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Nadciśnienie Tętnicze 2011; 15: 55-82.
12. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
13. Lee A.F.C., Dick J.B.C., Bonnar C.E. et al.: Lisinopril improves arterial function in hyperlipidaemia. Clin. Scien. 1999; 96: 441-448.
14. Reisin E., Weir M.R., Falkner B. et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients. A multicenter placebo-controlled trial. Hypertension 1997; 30 (part 1): 140-145.
15. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
16. Andersen N.H., Poulsen P.L., Knudsen S.T. et al.: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273-77.
17. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-67.
18. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349(9068): 1787-1792.
19. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
20. Brilla C.G., Funck R.C., Rupp H.: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
21. Beevers D.G., Blackwood R.A., Garnham S.: Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. Am. J. Cardiol. 1991; 67(1): 59-62.
22. Jakubowski P., Drożdż J.: Inhibitory konwertazy angiotensyny w niewydolności serca. Terapia 2011; 3: 24-27.
23. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23): 2312-2318.
24. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal 2012; 33: 1787-1847.
25. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906): 1115-1122.
26. Popescu B.A., Macor F., Antonini-Canterin F. et al.: GISSI-3 Echo Substudy Investigators. Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). Am. J. Cardiol. 2004; 93(9): 1156-1159.
27. Pizzettib F., Turazzaa F.M., Franzosia M.G. et al.: Cardiovascular medicine Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86: 527-532.
28. Latini R., Santoro E., Masson S. et al.: GISSI-3 Investigators. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis. 2000; 2(3): 185-190.
29. Adamska-Dyniewska H.: Lizynopryl – hydrofilny inhibitor konwertazy angiotensyny. Leki współczesne, które warto znać. Wydawnictwo TTM, Łódź 2000: 94-107.
30. Savino L.B., Haushalter N.M.: Lisinopril-induced “scalded mouth syndrome”. Ann. Pharmacother. 1992; 26: 1381-1382.
31. Hateboer N., van Dijk M., Bogdanova N. et al.: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353(9147): 103-107.
32. Schrier R.: Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2009; 20: 1888-1893.
33. Perrone R., Ruthazer R., Terrin N.: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001; 38: 777-784.
34. Fick G., Johnson A., Hammond W., Gabow P.: Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995; 5: 2048-2056.
35. Chapman A.B., Torres V.E., Perrone R.D. et al.: The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 2010; 5: 102-109.
36. Perrone R.D., Abebe K.Z., Schrier R.W. et al.: HALT PKD Study Group, Meyers C.M.: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 2508-2515.
37. Torres V.E., Chapman A.B., Perrone R.D., Bae K.T. et al.: HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012; 81: 577-5785.
38. Torres V.E., Chapman A.B., Devuyst O. et al.: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012 [online: doi: 10.1056/NEJMoa1205511].
2. Opie L.H.: Inhibitory konwertazy angiotensyny. Postęp trwa. Via Medica, Gdańsk 2000: 219-223.
3. Barylski M., Górska-Ciebiada M.: Lizinopril – praktyczne wskazania do stosowania w terapii chorób układu sercowo-naczyniowego. Geriatria 2011; 5: 110-121.
4. Gu Q., Burt V.L., Dillon C.F. et al.: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. Circulation 2012; 126(17): 2105-2114.
5. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
6. Izzo J.L., Weinberg M.S., Hainer J.W. et al.: Antihypertensive Efficacy of Candersartan-Lisinopril in Combination vs Up-Titration of Lisinopril: The AMAZE Trials. J. Clin. Hypertens. 2004; 6: 485-93.
7. Malacco E., Santonastaso M., Vari N.A. et al.: Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-65.
8. Belz G.G., Kirch W., Kleinbloesem C.H.: Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin. Pharmacokinet. 1988 Nov; 15(5): 295-318.
9. Shionoiri H., Ueda S., Gotoh E. et al.: Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. J. Cardiovasc. Pharmacol. 1990; 16(6): 905-9.
10. Thürig C., Böhlen L., Schneider M.: Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur. J. Clin. Pharmacol. 1995; 49(1-2): 21-6.
11. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Nadciśnienie Tętnicze 2011; 15: 55-82.
12. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
13. Lee A.F.C., Dick J.B.C., Bonnar C.E. et al.: Lisinopril improves arterial function in hyperlipidaemia. Clin. Scien. 1999; 96: 441-448.
14. Reisin E., Weir M.R., Falkner B. et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients. A multicenter placebo-controlled trial. Hypertension 1997; 30 (part 1): 140-145.
15. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
16. Andersen N.H., Poulsen P.L., Knudsen S.T. et al.: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273-77.
17. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-67.
18. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349(9068): 1787-1792.
19. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
20. Brilla C.G., Funck R.C., Rupp H.: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
21. Beevers D.G., Blackwood R.A., Garnham S.: Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. Am. J. Cardiol. 1991; 67(1): 59-62.
22. Jakubowski P., Drożdż J.: Inhibitory konwertazy angiotensyny w niewydolności serca. Terapia 2011; 3: 24-27.
23. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23): 2312-2318.
24. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal 2012; 33: 1787-1847.
25. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906): 1115-1122.
26. Popescu B.A., Macor F., Antonini-Canterin F. et al.: GISSI-3 Echo Substudy Investigators. Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). Am. J. Cardiol. 2004; 93(9): 1156-1159.
27. Pizzettib F., Turazzaa F.M., Franzosia M.G. et al.: Cardiovascular medicine Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86: 527-532.
28. Latini R., Santoro E., Masson S. et al.: GISSI-3 Investigators. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis. 2000; 2(3): 185-190.
29. Adamska-Dyniewska H.: Lizynopryl – hydrofilny inhibitor konwertazy angiotensyny. Leki współczesne, które warto znać. Wydawnictwo TTM, Łódź 2000: 94-107.
30. Savino L.B., Haushalter N.M.: Lisinopril-induced “scalded mouth syndrome”. Ann. Pharmacother. 1992; 26: 1381-1382.
31. Hateboer N., van Dijk M., Bogdanova N. et al.: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353(9147): 103-107.
32. Schrier R.: Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2009; 20: 1888-1893.
33. Perrone R., Ruthazer R., Terrin N.: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001; 38: 777-784.
34. Fick G., Johnson A., Hammond W., Gabow P.: Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995; 5: 2048-2056.
35. Chapman A.B., Torres V.E., Perrone R.D. et al.: The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 2010; 5: 102-109.
36. Perrone R.D., Abebe K.Z., Schrier R.W. et al.: HALT PKD Study Group, Meyers C.M.: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 2508-2515.
37. Torres V.E., Chapman A.B., Perrone R.D., Bae K.T. et al.: HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012; 81: 577-5785.
38. Torres V.E., Chapman A.B., Devuyst O. et al.: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012 [online: doi: 10.1056/NEJMoa1205511].